Facing a potential $15B-$20B revenue cliff by 2030 due to patent expirations and decreasing COVID-19 product sales, Pfizer Inc. is strategically acquiring biotech assets, including a promising GLP-1 drug candidate. This move aims to strengthen its position in the fast-growing metabolic market as it seeks to combat a recent underperforming stock status. Despite reaffirming its 2026 revenue forecast between $59.5 billion to $62.5 billion, analyst ratings remain cautious, with a current 'Underperform' designation and a $25 price target.
“On the other hand, the company recently stated that it plans to support the dividend at its current level as it works through its headwinds. The stock currently offers a lofty 6.3% yield...”
“That said, the real reason to buy Pfizer is what happened after its GLP-1 drug setback. The company quickly acquired a biotech with a promising GLP-1 drug candidate, and then inked a distribution partnership with another pharma company developing a GLP-1 pill.”
“Pfizer Inc. (NYSE:PFE) was initiated with an Underperform rating and a $25 price target by RBC Capital on February 24, with the firm stating that it reflects an “insurmountable” $15B-$20B revenue cliff through 2030 with little near-term pipeline visibility seen to offset it.”
“We will announce the results of our Phase 1a trial in an upcoming conference and enter Phase 1b for the tumors that show the most promising signs of efficacy. That will probably be advancing so that we will have results that we can share by 2026.”
“Shares of Pfizer fell 3.3% on Feb. 3 after the company reaffirmed 2026 guidance, pointing to a revenue decline, driven by a ~$1.5 billion hit from patent cliffs and ongoing pressure from waning COVID-19 product sales.”
“The therapy has already been approved in China for diabetes and is currently under regulatory review for obesity, positioning Pfizer to potentially enter one of the world's fastest-growing metabolic markets.”
“Alexandre de Germay, Pfizer's chief international commercial officer, acknowledged ahead of the announcement that the company had lost our focus during the pandemic period, underscoring why rebuilding in high-demand therapeutic areas such as obesity could be central to its forward strategy.”
“For Pfizer, here are previews of two leading Pfizer Narratives to make comparison easier for you: ... Fair value in this Narrative: US$29.08 per share ... the last close of US$27.14: about 6.7% undervalued.”
“Analysts backing this view see obesity, oncology and other late stage therapies as key long run growth drivers ... assumes earnings rise to US$12.8b by around 2028.”
“This more cautious view leans on drug pricing pressure, loss of exclusivity on key products and tougher regulation as headwinds for revenue and margins. The Narrative assumes earnings reach about US$11.8b by 2028, with ... revenue shrinking faster ... revenue growth assumption: 6.76% annual decline.”
“However, it has lagged PFE’s 8.8% YTD uptick.”
“PFE, CME, QCOM, TSLA, IREN, CRWV and DIS all experienced unusual options activity last week.”